Search
Breast Cancer Clinical Trials in Canada
A listing of 72 Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 24 of 72
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Breast Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 72 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are .
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Recruiting
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +216 locations
Conditions: Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
Recruiting
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk of recurrence by nearly half, and death by a third. However, treatment with trastuzumab can result in cardiotoxicity, including heart failure, as well as the significant cost of treatment and the requirement for patients to attend the chemotherapy unit for treatment eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: The Ottawa Hospital Cancer Centre, Ottawa, Ontario
Conditions: Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Recruiting
Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have changed practice due to significant improvement in progression free survival (PFS) and overall survival (OS) seen in this disease setting. There is a genuine interest to use SG sequentially after... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: BC Cancer - Vancouver Center, Vancouver, British Columbia
Conditions: Breast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer:
* HR-positive (breast cancer cells that need estrogen or progesterone to grow)
* HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface);
* locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +254 locations
Conditions: Breast Cancer
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Research Site, Duarte, California +65 locations
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.
Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Katmai Oncology Group - Anchorage, Anchorage, Alaska +43 locations
Conditions: Breast Cancer
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +461 locations
Conditions: Breast Cancer
Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors
Recruiting
This study will examine whether a mobile app increases exercise levels in breast cancer survivors after treatments, reduces fatigue, and improves physical functions. This experimental study has 200 participants placed into one of two groups. One group will be asked to use the cancer-specific exercise app over 12 weeks, and the other group will receive the cancer exercise guidelines. Exercise will be measured by self-report questionnaires before and after the intervention and three months later.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Exercise Oncology Research Laboratory, Faculty of Kinesiology, Sport and Recreation, University of Alberta., Edmonton, Alberta
Conditions: Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Tucson, Arizona +173 locations
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position
Recruiting
Radiotherapy (RT) is common in the treatment of breast cancer, however, 95% of breast cancer patients are at risk of developing acute and chronic skin toxicities known as radiation dermatitis (RD) which includes symptoms such as pruritus, edema, erythema, and moist desquamation (MD). Patients with a larger breast size are especially at risk of developing RD. The severity of RD can impact patient's quality of life (QOL) and their ability to complete treatment. Skin care guidelines for patients re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Breast Cancer, Radiation Dermatitis
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Recruiting
Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalen... Read More
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
05/09/2025
Locations: NYU Langone Health, New York, New York +9 locations
Conditions: Breast Cancer, Breast Cancer Recurrent
13 - 24 of 72